Quality of life and symptoms improvement after 6 months treatment with roflumilast 500 μg daily in a large Greek COPD cohort

TLDR: Six-months treatment with roflumilast 500 μg daily of naive to roflUMilast large COPD cohort, showed significant and clinically meaningful early improvement in their MRC dyspnea index and their quality of life.

Abstract: Background and aims We evaluated the changes in MRC dyspnea index and CCQ questionnaire in Greek COPD patients treated with Roflumilast during a 6 month cohort study (ATLAS study). Materials and Methods Changes in CCQ questionnaire and MRC dyspnea score were evaluated in 2167 patients with severe chronic obstructive pulmonary disease (COPD), FEV1 (% pred) 49.1± 14.7 aged 70.5 ± 9.7 with a mean Body Mass Index of 29.1±4.8 (mean values) following treatment with Roflumilast for a six month observational period. Data were collected at baseline (V0), 3 rd (V1) and 6 th month (V2). Spirometric evaluation, (FEV1, FVC, FEV/FVC) and body weight measurement were also included. Results Total CCQ questionnaire demonstrated clinically relevant and statistically significant improvement between pre and 6-months post-treatment period (x±SD) Δ=-1.53±1.07, p Conclusion : Six-months treatment with roflumilast 500 μg daily of naive to roflumilast large COPD cohort, showed significant and clinically meaningful early improvement in their MRC dyspnea index and their quality of life.